Proteasome inhibition modeling nigral neuron degeneration in Parkinson’s disease
Authors:
Open Access
- 15 September 2010
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 115 (1) , 188-199
Abstract
J. Neurochem. (2010) 115, 188–199. Impairment of the ubiquitin proteasome system (UPS) has been proposed to play an important role in the pathogenesis of Parkinson’s disease (PD). Mice with UPS impairment in the nigra have been used for investigating mechanisms underlying neurodegeneration and for testing pre‐clinical drugs to treat PD. However, the pathological, biochemical and behavioral features of UPS impairment animal model of PD have not been fully evaluated. For this purpose, we developed a UPS impairment model of nigral dopamine (DA) neuron degeneration by microinjection with proteasome inhibitors lactacystin, PSI or MG‐132 into the medial forebrain bundle (iMFB) of C57BL/6 mice and then systematically examined the animal’s locomotor activities, and various pathological and biochemical markers of PD. We found that lactacystin iMFB induced a sustained DA neuron degeneration, which can be reproduced by PSI iMFB and MG‐132 iMFB. In the animal model, DA neuron degenerated preferentially in the substantia nigra, accompanied by profound inhibition of proteasomal activity, activation of caspase 3, elevated insoluble ubiquitin conjugates and α‐synuclein positive inclusion‐like granules, activated glia, and decreased motor activities. Thus, this model recapitulates many neuropathological and behavioral features of PD, rendering it likely suitable for studying the mechanisms of nigral DA neuron degeneration and for testing the potential anti‐PD medications.Keywords
This publication has 50 references indexed in Scilit:
- A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouseNeuroscience, 2009
- Targets for neuroprotection in Parkinson's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's diseaseNature Neuroscience, 2009
- Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final stepsApoptosis, 2009
- Animal models of Parkinson’s disease progressionActa Neuropathologica, 2008
- In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease?Experimental Neurology, 2008
- The proteasomal inhibition model of Parkinson's disease: “Boon or bust”?Annals of Neurology, 2006
- Lack of nigrostriatal pathology in a rat model of proteasome inhibitionAnnals of Neurology, 2006
- Proteasome inhibition and Parkinson's disease modelingAnnals of Neurology, 2006
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004